NCT05100069 Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
| NCT ID | NCT05100069 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Non-small Cell Lung Cancer (NSCLC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-11-01 |
| Primary Completion | 2030-09-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.
Eligibility Criteria
Inclusion criteria Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer. Exclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.